JP5183808B2 - 置換トリアゾロ−ピリダジン誘導体 - Google Patents

置換トリアゾロ−ピリダジン誘導体 Download PDF

Info

Publication number
JP5183808B2
JP5183808B2 JP2011525250A JP2011525250A JP5183808B2 JP 5183808 B2 JP5183808 B2 JP 5183808B2 JP 2011525250 A JP2011525250 A JP 2011525250A JP 2011525250 A JP2011525250 A JP 2011525250A JP 5183808 B2 JP5183808 B2 JP 5183808B2
Authority
JP
Japan
Prior art keywords
compound
compounds
acid
deuterium
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011525250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501346A (ja
JP2012501346A5 (https=
Inventor
ハーブソン，スコット
Original Assignee
コンサート ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンサート ファーマシューティカルズ インコーポレイテッド filed Critical コンサート ファーマシューティカルズ インコーポレイテッド
Publication of JP2012501346A publication Critical patent/JP2012501346A/ja
Publication of JP2012501346A5 publication Critical patent/JP2012501346A5/ja
Application granted granted Critical
Publication of JP5183808B2 publication Critical patent/JP5183808B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011525250A 2008-08-29 2009-08-28 置換トリアゾロ−ピリダジン誘導体 Expired - Fee Related JP5183808B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9329308P 2008-08-29 2008-08-29
US61/093,293 2008-08-29
PCT/US2009/055427 WO2010025407A1 (en) 2008-08-29 2009-08-28 Substituted triazolo-pyridazine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013004449A Division JP5373982B2 (ja) 2008-08-29 2013-01-15 置換トリアゾロ−ピリダジン誘導体

Publications (3)

Publication Number Publication Date
JP2012501346A JP2012501346A (ja) 2012-01-19
JP2012501346A5 JP2012501346A5 (https=) 2012-10-18
JP5183808B2 true JP5183808B2 (ja) 2013-04-17

Family

ID=41721962

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011525250A Expired - Fee Related JP5183808B2 (ja) 2008-08-29 2009-08-28 置換トリアゾロ−ピリダジン誘導体
JP2013004449A Expired - Fee Related JP5373982B2 (ja) 2008-08-29 2013-01-15 置換トリアゾロ−ピリダジン誘導体
JP2013194060A Pending JP2014058518A (ja) 2008-08-29 2013-09-19 置換トリアゾロ−ピリダジン誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013004449A Expired - Fee Related JP5373982B2 (ja) 2008-08-29 2013-01-15 置換トリアゾロ−ピリダジン誘導体
JP2013194060A Pending JP2014058518A (ja) 2008-08-29 2013-09-19 置換トリアゾロ−ピリダジン誘導体

Country Status (17)

Country Link
US (4) US8003646B2 (https=)
EP (2) EP2328414B1 (https=)
JP (3) JP5183808B2 (https=)
KR (1) KR20110063479A (https=)
CN (2) CN104098578A (https=)
AU (1) AU2009285533B2 (https=)
BR (1) BRPI0912928A2 (https=)
CA (1) CA2735549A1 (https=)
DK (1) DK2328414T3 (https=)
EA (1) EA020071B1 (https=)
ES (1) ES2451542T3 (https=)
HR (1) HRP20140195T1 (https=)
MX (1) MX2011002278A (https=)
PL (1) PL2328414T3 (https=)
PT (1) PT2328414E (https=)
WO (1) WO2010025407A1 (https=)
ZA (1) ZA201102123B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014058518A (ja) * 2008-08-29 2014-04-03 Concert Pharmaceuticals Inc 置換トリアゾロ−ピリダジン誘導体

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2340782A4 (en) 2008-10-03 2014-04-02 Inst Alberto Luiz Coimbra De Pos Graduacao E Pesquisa De Engenharia Coppe Ufrj METHOD AND DEVICE FOR REMOVING METAL FRAGMENTS AND METAL ELEMENTS FROM TOOTH ROOT CHANNELS
US8501738B2 (en) 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
EP2768834B1 (en) * 2011-10-20 2016-04-27 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2802569B1 (de) 2012-01-11 2016-01-06 Bayer Intellectual Property GmbH Tetrazol-5-yl- und triazol-5-yl-arylverbindungen und ihre verwendung als herbizide
US20150158870A1 (en) * 2012-05-11 2015-06-11 Concert Pharmaceuticals Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
EP2847195A1 (en) * 2012-05-11 2015-03-18 Concert Pharmaceuticals Inc. Form 2 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2015052173A1 (en) 2013-10-10 2015-04-16 Basf Se Tetrazole and triazole compounds and their use as herbicides
WO2015052178A1 (en) 2013-10-10 2015-04-16 Basf Se 1,2,5-oxadiazole compounds and their use as herbicides
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
CN104353078B (zh) * 2014-11-24 2017-10-24 王寿世 一种麻醉用药物组合物
CN104474549A (zh) * 2014-11-24 2015-04-01 王寿世 异丙酚和gabaa受体拮抗剂在制备麻醉药物中的用途
US10026332B1 (en) 2017-04-10 2018-07-17 Jasmine Gupta Method to deliver contextual educational information utilizing smart wearables
SG11202109526PA (en) * 2019-03-18 2021-10-28 Neurocycle Therapeutics Inc Use of gabaa receptor modulators for treatment of pain
WO2023205722A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321162D0 (en) 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
ES2194205T3 (es) * 1996-07-25 2003-11-16 Merck Sharp & Dohme Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba.
YU43800A (sh) * 1998-01-21 2002-12-10 Merck Sharp & Dohme Limited Triazolo-piridazin derivati kao ligandi za gaba receptore
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
JP2002535407A (ja) * 1999-01-27 2002-10-22 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体のリガンドとしてのトリアゾロピリダジン誘導体
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE60315876T2 (de) * 2002-11-28 2008-05-21 Neurosearch A/S Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US20080051422A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-Aminoquinazoline derivatives and methods of use thereof
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
CA2735549A1 (en) 2008-08-29 2010-03-04 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014058518A (ja) * 2008-08-29 2014-04-03 Concert Pharmaceuticals Inc 置換トリアゾロ−ピリダジン誘導体

Also Published As

Publication number Publication date
CN104098578A (zh) 2014-10-15
HRP20140195T1 (hr) 2014-04-11
EP2328414A4 (en) 2011-11-16
ES2451542T3 (es) 2014-03-27
JP2012501346A (ja) 2012-01-19
WO2010025407A1 (en) 2010-03-04
KR20110063479A (ko) 2011-06-10
EP2328414A1 (en) 2011-06-08
CN102176826A (zh) 2011-09-07
US8003646B2 (en) 2011-08-23
EP2716158A1 (en) 2014-04-09
EA201100409A1 (ru) 2011-10-31
US20100056529A1 (en) 2010-03-04
DK2328414T3 (en) 2014-03-10
JP5373982B2 (ja) 2013-12-18
EP2328414B1 (en) 2013-12-11
US20150111895A1 (en) 2015-04-23
AU2009285533A2 (en) 2011-04-21
US8399467B2 (en) 2013-03-19
JP2013100322A (ja) 2013-05-23
US8921366B2 (en) 2014-12-30
CN102176826B (zh) 2014-08-20
AU2009285533B2 (en) 2014-02-13
PL2328414T3 (pl) 2014-05-30
BRPI0912928A2 (pt) 2015-08-04
US20130225590A1 (en) 2013-08-29
US20120004236A1 (en) 2012-01-05
CA2735549A1 (en) 2010-03-04
MX2011002278A (es) 2011-04-14
EA020071B1 (ru) 2014-08-29
AU2009285533A1 (en) 2010-03-04
JP2014058518A (ja) 2014-04-03
PT2328414E (pt) 2014-03-17
ZA201102123B (en) 2011-12-28

Similar Documents

Publication Publication Date Title
JP5183808B2 (ja) 置換トリアゾロ−ピリダジン誘導体
US20090137457A1 (en) Pyrimidinedione derivatives
US8609673B2 (en) Vandetanib derivatives
JP2016512831A (ja) 重水素化されたパルボシクリブ
US20090192188A1 (en) Tetrahydroisoquinoline derivatives
US8071596B2 (en) Endothelin receptor antagonists
US8367674B2 (en) Piperazine derivatives
WO2018013625A1 (en) Deuterated miconazole
WO2009126844A2 (en) Derivatives of 3-(2-hydroxy-5-methyphenyl)-n,n-diisopropyl-3-phenylpropylamine and methods of use thereof
US20110301113A1 (en) Pyridineamine derivatives
US20100120786A1 (en) Piperazine Derivatives
US20090197899A1 (en) 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
WO2009099620A1 (en) 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
AU2014202485A1 (en) Substituted triazolo-pyridazine derivatives
US20110104158A1 (en) Deuterium bearing analogs of anastrozole as aromatase inhibitors for the treatment of breast cancer
WO2010002451A1 (en) Naphthyridin derivatives
WO2009151613A1 (en) Oxybutynin derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120828

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20120828

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130115

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160125

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees